Fulminant hepatitis-A in a child using sodium valproate therapy: Case report Sodyum valproat tedavisi alan bir çocukta fulminan hepatit-A


ÇELTİK C., TURAN Ç., Acipayam C., Küçükuǧurluoǧlu Y., Karasalihoǧlu S.

Turkiye Klinikleri Pediatri, vol.19, no.2, pp.176-179, 2010 (Scopus)

  • Publication Type: Article / Article
  • Volume: 19 Issue: 2
  • Publication Date: 2010
  • Journal Name: Turkiye Klinikleri Pediatri
  • Journal Indexes: Scopus
  • Page Numbers: pp.176-179
  • Keywords: Child, Hepatic encephalopathy, Hepatitis A, Hepatitis A vaccines, Liver failure, acute, Valproic acid
  • Trakya University Affiliated: Yes

Abstract

The risk of fulminant liver failure due to hepatitis A infection increases in the patients with underlying chronic liver diseases and hepatotoxic drug-use. In this case report, we aimed to emphasize the development of fulminant liver failure due to hepatitis A infection and importance of hepatitis A vaccination in these cases. A five-year age boy who treated with sodium valproate for three years was admitted with the symptoms of fulminant liver failure and encephalopathy to our emergency clinic. Hepatitis A IgM-antibody was found positive and serum sodium valproate level was mildly elevated. In conclusion, fulminant progression risk due to hepatitis-A infection increase in the patients using hepatotoxic drug such as sodium valproate. Therefore, hepatitis-A vaccination for these cases is important for decreasing the risk of fulminant hepatitis. Copyright © 2010 by Türkiye Klinikleri.